Latest Headlines

Latest Headlines

FDA declines to approve Dainippon's epilepsy drug

Last fall, when Dainippon Sumitomo Pharma announced that it had inked a deal to buy Sepracor for $2.6 billion, the Japanese pharma company cited the once-daily epilepsy drug Stedesa as one of the

Sepracor chief exits as Dainippon moves in

Sepracor is losing its top executive but not its name in an overhaul following its acquisition by Japan's Dainippon Sumitomo Pharma. Adrian Adams, the company's president and CEO, has stepped down

Sepracor merges and CEO Adams jumps to Inspire

With the $2.6 billion acquisition of Sepracor by Dainippon Sumitomo drawing to a close soon, the developer's CEO is on his way over to take the helm at Raleigh, NC-based Inspire Pharmaceuticals.

Dainippon files for approval of blockbuster schizophrenia drug

Dainippon Sumitomo has filed for FDA approval of its prospective blockbuster schizophrenia drug lurasidone, beating its own timetable as the Japanese pharma giant stays on course toward an expected

Sepracor CEO in line for $11M golden handshake

Japan's Dainippon Sumitomo has completed its $2.6 billion deal to buy Sepracor and has set aside a tidy package of $11 million for CEO Adrian Adams (photo). The Boston Business Journal checked out

Sepracor investors try to derail $2.6B Dainippon buyout

Two of Sepracor's stockholders are shouting foul in a lawsuit aimed at derailing Dainippon Sumitomo's $2.6 billion acquisition pact, hoping for a richer deal in the process. Close to a week ago,

Sepracor shareholders sue to block deal

Sepracor shareholders aren't happy. They're so unhappy that management agreed to sell itself to Japan's Dainippon Sumitomo Pharma at $23 per share that they've sued, calling the price unfair and

Sepracor says it's staying put

Marlborough, MA-based Sepracor was quick to reassure the Boston biotech community that Dainippon's $2.6 billion acquisition of the company wouldn't interfere with its local operations. The Japanese

At $2.6B, is Sepracor the best buy for Dainippon?

Another Japanese pharma has snapped up a U.S. drugmaker. This time, it's Dainippon Sumitomo Pharma, which will pay $2.6 billion for Sepracor mainly to get access to the latter's sales network.

Dainippon grabs Sepracor for $2.6B

Spurred by a stagnating home drug market, Japan's Dainippon Sumitomo has struck a deal to buy Sepracor for $2.6 billion. Backed by bridge loans, Dainippon says it will pay $23 a share for Sepracor, a